Women remain underrepresented in early stage clinical trials. We looked into the misconceptions behind this insidious issue, and the ways the clinical trial ecosystem could break the glass barriers to women's participation in clinical research. https://t.co/KtcBYAgga6

Is pharma shying away from tackling the unmet need in substance use disorders? @ufulti dissects the possible reasons behind this apparent neglect. https://t.co/5xrcyGAPxT

In an exclusive, @OlemaOncology discusses two Phase III trial plans for ER+, HER2- breast cancer. Senior reporter @WillNewton19 has more on how Olema plans to tackle the notoriously tough-to-treat disease with a dual-mechanism oral SERD:

Have you ever thought about recruiting robots for your clinical trial operations? The #clinicaltrials industry is yet to embrace the full advantage of deploying a #bot workforce, @ufulti reports. https://t.co/tGkLREkxc5

In an exclusive, @AshvatthaTx CEO Jeff Cleland delves into plans for a potential trial in #LongCovid after pivoting from acute Covid-19 infections. Read more about the trial's rationale, target population, and potential endpoints: https://t.co/Jbyx93q6Or

For #Psoriasis Awareness Month, we dove into the major upcoming late-stage trial results and completions in plaque psoriasis and psoriatic arthritis. Here’s the major trials you need to follow in the second half of 2022: https://t.co/LerSDKExPf

Axcella $AXLA previews plans for a registrational trial for AXA1125 in #LongCovid, including possible endpoints, on the heels of Phase IIa results announced yesterday. @WillNewton19 reports

A longstanding approach in Alzheimer's disease—the amyloid theory—is under scrutiny after reports of possible image fabrication in multiple journal articles. In a data-driven analysis, we look at the current state of AD trials based on the amyloid theory:

To commemorate Hepatitis Day, we take a look at GSK's bepirovirsen. While early Phase IIb data shows the candidate has potential to deliver HBV functional cure, experts are still craving for more data. Urte Fultinaviciute (@ufulti) investigates.

We've updated our #LongCovid trials calendar to bring you four major trial readouts expected in the next year, @WillNewton19 reports: https://t.co/2ntMTQNuwF And ICYMI, Dr. Fauci discussed the crucial need for standardised endpoints in long Covid trials: https://t.co/TX55F76ZXS

With @michaelpollan documentary on #psychedelics landing on #Netflix, it is important to note that this field is yet to prove its value in clinical trials. Read @ufulti feature on the challenges psychedelic clinical trials face.

There are a variety of noninvasive NASH tests currently available and under investigation—but how can they be optimised? @pharmarey reports. https://t.co/sxSQvkWcm3

Senior reporter @WillNewton19 spoke to @AristeaTx on its Phase III trial plans in palmoplantar pustulosis if the ongoing Phase IIb delivers positive results

With all new clinical trial applications for Europe expected to go through the new system from January 2023, CTIS uptake is still slow. Read more for actionable advice for sponsors so they don't get left behind.

Cullinan Oncology gave as an exclusive study design preview of its upcoming Phase IIb trial in non-small cell lung cancer. $CGEM

Non-profit organizations such as DNDi are driving efforts to find new therapies for #NTDs — but the support of the pharmaceutical industry is still crucial, says our R&D Director Laurent Fraisse. @PharmaTechFocus @fraisse47

While many CROs and sponsors already use eTMF, there are still ways for users to make the most of the technology. There are approaches to lift the burden off clinical trial sites, as well as making sure the system is inspection- or audit-ready.

I asked Dr. Fauci about the challenges of studying long Covid in clinical trial, and heard his takes on Covid misinformation and public perception: https://t.co/aeSRlplxvp

Senior reporter @WillNewton19 asked Dr Anthony Fauci about the challenges to selecting clinical trial endpoints for long Covid studies during a @NatPress Q&A. Fauci discussed ongoing efforts to study long Covid-19, misinformation, and more: https://t.co/w3AkFJNrzo

We spoke to Liam Paschall (@LPaschall1202) of @Parexel on reasons why transgender and nonbinary individuals may not participate in clinical trials, and “baby steps” the sector can do to help boost engagement in studies